GLP-1 Collective

Policy Tracker · Patient Lens · July 18, 2026

Medicaid in New York will now pay for Wegovy and Zepbound

While lawsuits pile up over how Novo Nordisk and Lilly priced these drugs, one state just made coverage the easier question to answer.

5 developments affecting GLP-1 access were tracked on Friday, July 17, 2026, across 2 categories. Each entry links to the full record.

## Coverage and cost

**[New York Medicaid now covers Wegovy and Zepbound for weight loss](/fda/medicaid-action-ny-glp1-diabetes-only-policy)**.

## Courts and enforcement

**[Herrerra sues Eli Lilly over GLP-1 marketing claims](/lawsuits/cl-73636088)**.

**[Patient sues Novo Nordisk over GLP-1 pricing and marketing](/lawsuits/cl-73637844)**.

**[Millwood sues Novo Nordisk over GLP-1 pricing and marketing](/lawsuits/cl-73627247)**.

**[Patient sues Novo Nordisk over Ozempic and Wegovy claims](/lawsuits/cl-73632294)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.